Jianbo Lin - Publications

UFMylation Suppresses Hepatocellular Carcinoma Metastasis by Inhibiting β-Catenin-Driven Hybrid EMT and NK Cell Evasion.

Journal: Cancer research

Published: October 20, 2025

Liver ischemia-reperfusion promotes tumor metastasis via neutrophil-endothelial interactions: targeting ICAM1 to prevent metastatic recurrence.

Journal: Journal of translational medicine

Published: September 02, 2025

Transcriptomic landscape of NK cell-related genes in hepatocellular carcinoma: associations with prognosis and therapeutic response.

Journal: Discover oncology

Published: April 21, 2025

Benefits of entecavir therapy in HBV-related hepatocellular carcinoma patients with compensated cirrhosis after hepatectomy: A ten-year retrospective cohort study.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: October 24, 2024

HBcrAg is associated with prognosis of hepatitis B virus-related hepatocellular carcinoma in patients after hepatectomy undergoing antiviral therapy.

Journal: International journal of cancer

Published: May 23, 2024

Aspartate β-hydroxylase (ASPH) Accelerates Intrahepatic Cholangiocarcinoma Metastasis via Upregulating SHH Signaling Pathway.

Journal: Current protein & peptide science

Published: December 14, 2022

Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma.

Journal: World journal of surgical oncology

Published: October 08, 2022

Radiomics-Based Preoperative Prediction of Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma Using Contrast-Enhanced Computed Tomography.

Journal: Annals of surgical oncology

Published: January 31, 2022

SNHG7 Facilitates Hepatocellular Carcinoma Occurrence by Sequestering miR-9-5p to Upregulate CNNM1 Expression.

Journal: Cancer biotherapy & radiopharmaceuticals

Published: May 14, 2020

MiR-876-5p acts as an inhibitor in hepatocellular carcinoma progression by targeting DNMT3A.

Journal: Pathology, research and practice

Published: March 11, 2018